Multiple System Atrophy
New multiple system atrophy research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), one phase 2 alpha-synuclein antibody trial was negative, while symptom-focused care and blood NfL-based diagnosis tools moved forward in the available reports. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Disease-modifying trials. In the months covered, one trial was clearly negative, and another report raised a possible liver-injury signal.
- Brain stimulation symptoms. The evidence base grew, from pooled rTMS trials to a short tACS randomized trial.
- Blood pressure symptoms. A small randomized posture study showed targeted effects, while an exploratory medication study had mixed results.
- Swallowing and airway care. Reports moved from mixed-diagnosis PEG data to a matched analysis focused on MSA.
- Better-supported diagnosis. In the months covered, multi-test diagnosis became more common, and a large study supported blood NfL.
New
September 2026
- Tube feeding. One center linked tube feeding to slightly longer survival.
- Non-drug stimulation. A short trial improved movement in cerebellar-type MSA.
- Liver injury risk. A drug trial reported liver injury and an unconfirmed genetic signal.
- Sleep breathing. MSA was linked to worse sleep breathing and more autonomic problems.
August 2026
- Blood damage marker. A blood marker of nerve damage helped distinguish early MSA from Parkinsons.
- MRI decline markers. MSA-related MRI changes were linked to faster symptom worsening.
- Nutrition and outcomes. Poor nutrition and faster weight loss were linked to shorter survival.
July 2026
- Brain stimulation. Pooled small trials linked rTMS to better movement and mood scores.
- Standing blood pressure. After switching to placebo, symptoms and standing blood pressure worsened.
- Imaging clues. Dopamine scans and MRI measures helped separate look-alike conditions.
- Blood test signals. Blood markers separated MSA from healthy people more than Parkinson's.
June 2026
- Symptom change. Symptom and movement scores rose steadily over about a year.
- Sweat function test. A sweat test matched severity and was linked to survival.
- Balance training. Supervised virtual reality training improved balance in a small series.
- Test patterns. Blood and brain tests showed differences, but need validation.
May 2026
- Head-up bed tilt. Head-up bed tilt improved some standing and daytime blood pressure measures.
- Marker combinations. Combining markers separated MSA from similar conditions better than one test.
- Lab method effects. Spinal fluid misfolded-protein results varied with the lab method used.
- Progression and survival. Faster symptom worsening and certain milestones were linked to shorter survival.
April 2026
- Antibody trial outcome. In a phase 2 trial, an alpha-synuclein antibody did not slow MSA progression compared with placebo.
- Apomorphine for fluctuations. In registry data, continuous apomorphine infusion was linked to fewer motor fluctuations for some people with MSA, with side effects reported.
- Using multiple tests. In research studies, combining tests (such as MRI measures and spinal fluid panels) separated MSA from similar disorders better than single tests.
- Support-cell changes. Studies reported changes in support cells that were associated with signals of nerve-fiber damage.
March 2026
- Alpha-synuclein tests. Alpha-synuclein testing in spinal fluid and skin helped separate MSA from conditions that can look similar.
- Eyes-closed balance testing. Balance measures that challenge stability (such as eyes-closed or more dynamic standing) distinguished MSA from Parkinson’s disease better than quiet standing.
- One-time blood marker. A single early blood neurofilament light chain level was linked to later disease progression in one cohort study.
February 2026
- Tests to support diagnosis. Several studies reported that biologic tests, including skin-based alpha-synuclein testing, can help distinguish MSA from similar conditions, although results were not consistent for every person.
- Measuring progression. Imaging, spinal fluid markers, and nerve testing each reflected different aspects of MSA, and several measures did not closely track symptom scores, suggesting no single marker captures the full picture.
- Early treatment reports. Small real-world reports described symptom changes with apomorphine infusion and with protirelin in the cerebellar subtype, and one case report linked starting duloxetine to worsening low sodium.
- Biology and genetics studies. Cell and mouse studies linked inflammation and mitochondrial stress to MSA-related changes, and a large genetics analysis reported different X-chromosome risk signals in females and males without near-term use for individual prediction.
January 2026
- Feeding tube use. Feeding tubes were linked to longer survival after swallowing problems.
- Clearer diagnosis. New criteria and spinal fluid tests better separated MSA from Parkinsons.
- Faster decline pattern. One brain pattern was linked to earlier falls and shorter survival.
- Common pain. Surveys found frequent pain, often at night and in muscles.
Get the monthly update by email
Subscribe here to receive an email when a new monthly multiple system atrophy update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).